ClinicalTrials.gg
CompletedNCT07532304Updated Aug 25, 2026

A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646)

A Phase 1 interventional study of Bictegravir/emtricitabine/tenofovir alafenamide and Dolutegravir in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Researchers are looking for new treatments for people living with HIV-1(Human Immunodeficiency Virus Type 1). HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system.

HIV-1 treatments, called ART (antiretroviral therapy), involve taking medicines to lower the amount of HIV-1 virus in the body. Standard ART may include Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) and Dolutegravir (DTG).

MK-4646 is a trial medicine designed to treat HIV-1. Before giving a trial medicine to people with a health condition, researchers first do trials in healthy people.

The goals of this study are to learn:

  • If taking MK 4646 together with BIC/FTC/TAF or DTG changes the amount of these ARTs in the blood over time.
  • About the safety of MK-4646 and if people tolerate it. Tolerate means participants will receive treatment in the trial unless they need to stop it due to health problems.
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is in good health before randomization
  • Has a (BMI) between 18 and 32 kg/m\^2, inclusive

Exclusion criteria

Exclusion Criteria:

  • Has a history of endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Has a history of cancer ()
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Treatment A: bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)

    Participants will receive a single oral dose of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).

    Drug: Bictegravir/emtricitabine/tenofovir alafenamide

  • Experimental
    Treatment B: dolutegravir (DTG)

    Participants will receive a single oral dose of dolutegravir (DTG).

    Drug: Dolutegravir

  • Experimental
    Treatment C: MK-4646 + bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)

    Participants will receive a single oral dose of MK-4646 coadministered with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).

    Drug: Bictegravir/emtricitabine/tenofovir alafenamide · Drug: MK4646

  • Experimental
    Treatment D: MK-4646 + dolutegravir (DTG)

    Participants will receive a single oral dose of MK-4646 coadministered with dolutegravir (DTG).

    Drug: Dolutegravir · Drug: MK4646

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-∞) of Bictegravir

    Blood samples will be collected to determine the AUC0-∞ of bictegravir.

    Time frame: At designated timepoints (up to approximately 72 hours post dose)

  2. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-∞) of Emtricitabine

    Blood samples will be collected to determine the AUC0-∞ of emtricitabine.

    Time frame: At designated timepoints (up to approximately 72 hours post dose)

  3. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-∞) of Tenofovir Alafenamide

    Blood samples will be collected to determine the AUC0-∞ of tenofovir alafenamide.

    Time frame: At designated timepoints (up to approximately 72 hours post dose)

  4. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-∞) of Tenofovir

    Blood samples will be collected to determine the AUC0-∞ of tenofovir.

    Time frame: At designated timepoints (up to approximately 72 hours post dose)

  5. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-∞) of Dolutegravir

    Blood samples will be collected to determine the AUC0-∞ of dolutegravir.

    Time frame: At designated timepoints (up to approximately 72 hours post dose)

Secondary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 44 days

  2. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 31 Days

  3. Maximum Plasma Concentration (Cmax) of Bictegravir

    Blood samples will be collected to determine the Cmax of bictegravir.

    Time frame: At designated timepoints (up to approximately 72 hours post dose)

  4. Plasma Concentration at 24 Hours (C24) of Bictegravir

    Blood samples will be collected to determine the C24 of bictegravir.

    Time frame: 24 hours post dose

  5. Time to Maximum Plasma Concentration (Tmax) of Bictegravir

    Blood samples will be collected to determine the Tmax of bictegravir.

    Time frame: At designated timepoints (up to approximately 72 hours post dose)

  6. Apparent Terminal Half-life (t½) of Bictegravir

    Blood samples will be collected to determine the t½ of bictegravir.

    Time frame: At designated timepoints (up to approximately 72 hours post dose)

  7. Maximum Plasma Concentration (Cmax) of Emtricitabine

    Blood samples will be collected to determine the Cmax of emtricitabine.

    Time frame: At designated timepoints (up to approximately 72 hours post dose)

  8. Plasma Concentration at 24 Hours (C24) of Emtricitabine

    Blood samples will be collected to determine the C24 of emtricitabine.

    Time frame: 24 hours post dose

  9. Time to Maximum Plasma Concentration (Tmax) of Emtricitabine

    Blood samples will be collected to determine the Tmax of emtricitabine.

    Time frame: At designated time points (up to approximately 72 hours post dose)

  10. Apparent Terminal Half-life (t½) of Emtricitabine

    Blood samples will be collected to determine the t½ of emtricitabine.

    Time frame: At designated timepoints (up to approximately 72 hours post dose)

  11. Maximum Plasma Concentration (Cmax) of Tenofovir Alafenamide

    Blood samples will be collected to determine the Cmax of tenofovir alafenamide.

    Time frame: At designated timepoints (up to approximately 72 hours post dose)

  12. Plasma Concentration at 24 Hours (C24) of Tenofovir Alafenamide

    Blood samples will be collected to determine the C24 of tenofovir alafenamide.

    Time frame: At designated time points (up to approximately 24 hours post dose)

  13. Time to Maximum Plasma Concentration (Tmax) of Tenofovir Alafenamide

    Blood samples will be collected to determine the Tmax of tenofovir alafenamide.

    Time frame: At designated time points (up to approximately 72 hours post dose)

  14. Apparent Terminal Half-life (t½) of Tenofovir Alafenamide

    Blood samples will be collected to determine the t½ of tenofovir alafenamide.

    Time frame: At designated timepoints (up to approximately 72 hours post dose)

  15. Maximum Plasma Concentration (Cmax) of Tenofovir

    Blood samples will be collected to determine the Cmax of tenofovir.

    Time frame: At designated timepoints (up to approximately 72 hours post dose)

  16. Plasma Concentration at (C24) of Tenofovir

    Blood samples will be collected to determine the C24 of tenofovir.

    Time frame: 24 hours post dose

  17. Time to Maximum Plasma Concentration (Tmax) of Tenofovir

    Blood samples will be collected to determine the Tmax of tenofovir.

    Time frame: At designated timepoints (up to approximately 72 hours post dose)

  18. Apparent Terminal Half-life (t½) of Tenofovir

    Blood samples will be collected to determine the t½ of tenofovir.

    Time frame: At designated timepoints (up to approximately 72 hours post dose)

  19. Maximum Plasma Concentration (Cmax) of Dolutegravir

    Blood samples will be collected to determine the Cmax of dolutegravir.

    Time frame: At designated timepoints (up to approximately 72 hours post dose)

  20. Plasma Concentration at (C24) of Dolutegravir

    Blood samples will be collected to determine the C24 of dolutegravir.

    Time frame: 24 hours post dose

  21. Time to Maximum Plasma Concentration (Tmax) of Dolutegravir

    Blood samples will be collected to determine the Tmax of dolutegravir.

    Time frame: At designated timepoints (up to approximately 72 hours post dose)

  22. Apparent Terminal Half-life (t½) of Dolutegravir

    Blood samples will be collected to determine the t½ of dolutegravir.

    Time frame: At designated timepoints (up to approximately 72 hours post dose)

07

Study locations

1 site
  • Pinnacle Research Group ( Site 0001)
    Anniston, Alabama 36207, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2026 to primary completion in Jul 2026, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
Apr 15, 2026
StartActual
May 11, 2026
Primary completionActual
Jul 23, 2026
CompletionActual
Jul 23, 2026
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07532304
Responsible party
Sponsor
First posted
Apr 15, 2026
Start date
May 11, 2026
Primary completion
Jul 23, 2026
Completion
Jul 23, 2026
Last update
Aug 25, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide · Dolutegravir · MK4646

Start the discussion